Antiplatelet therapy: Controversial aspects

Thrombosis Research

Volumn 129, Issue 3, 2012, Pages 225-229

  Coccheri, Sergio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATOPAXAR; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; ELINOGREL; PRASUGREL; TICAGRELOR; TIROFIBAN; VORAPAXAR;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ADJUVANT THERAPY; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG TREATMENT FAILURE; DYSPNEA; FAMILY HISTORY; GAIN OF FUNCTION MUTATION; GASTROINTESTINAL HEMORRHAGE; GENOTYPE; GOUT; HEART INFARCTION; HEREDITY; HUMAN; LOSS OF FUNCTION MUTATION; METABOLISM; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SIDE EFFECT; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; URIC ACID BLOOD LEVEL;

ANIMALS; CARDIOVASCULAR DISEASES; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; GENOTYPE; HEMORRHAGE; HUMANS; PATIENT SELECTION; PHARMACOGENETICS; PHENOTYPE; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; TREATMENT FAILURE;

EID: 84857788662     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.10.036     Document Type: Review

References (35)

1. G. Davì, and C. Patrono Platelet activation and atherothrombosis N Engl Med 357 2007 2482 2494
2. Antithrombotic Trialist' Collaboration Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
3. S. Coccheri Antiplatelet drugs. Do we need new options? Drugs 70 2010 887 908
4. D.J. Angiolillo Variability in responsiveness to oral anti-platelet therapy Am J Cardiol 103 2009 24a 27A [Suppl]
5. P.G. Steg, S.H. Dorman, and P. Amarenco Atherothrombosis and the role of antiplatelet therapy J Thromb Haemost 9 Suppl. 8 2011 325 332
6. S. Coccheri Approaches to prevention of cardiovascular complications and events in diabetes mellitus Drugs 67 2007 997 1026 (Pubitemid 46744476)
7. F. Sofi, R. Marcucci, and A.M. Gori Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events: a meta-analysis Int J Cardiol 128 2008 166 171
8. G. Di Minno Aspirin resistance and platelet turnover: a 25-year old issue Nutr Metab Cardiovasc Dis 21 2011 542 545
9. L. Laine, and C. Hennekens Proton pump inhibitor and clopidogrel interaction: fact or function? Am J Gastroenterol 105 2010 34 41
10. F.Y. Hsiao, C.D. Mullins, Y.W. Wen, W.F. Huang, P.F. Chen, and Y.W. Tsai Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome Pharmacolepidemiol Drug Saf 20 2011 1043 1049
11. G. Kassimis, P. Davlouros, I. Xanthopoulou, E.F. Stavrou, A. Athanassiadou, and D. Alexopoulos CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention Thromb Res Aug 8 2011 [Epub ahead of print]
12. J.L. Mega, T. Simon, and J.P. Collet TIMI Study Group. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 2010 1821 1830
13. C. Combescure, P. Fontana, and N. Mallouk Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis J Thromb Haemost 8 2010 923 933
14. T. Bauer, H.J. Bouman, J.W. van Wakerum, N.F. Ford, J.M. ten Berg, and D. Taubert Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis BMJ 343 2011 d4588
15. M.J. Price, P.B. Berger, and P.S. Teirstein GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
16. M. Valgimigli, G. Campo, and N. de Cesare Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized, tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study Circulation 199 2009 3215 3222
17. D. Sibbing, S. Braun, and T. Morath Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 2009 849 856
18. J.P. Collet, J.S. Hulot, and A. Pena Cytochrome P4502C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
19. S.A. Mousa, W.P. Jeske, and J. Fareed Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist Clin Appl Thromb Hemost 2 2010 170 176
20. G. Montelascot, S.D. Wiviott, and E. Braunwald Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomized controlled trial Lancet 373 2009 723 731
21. U.S. Tantry, K.P. Bliden, and C. Wei First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with Ticagrelor vs Clopidogrel: the ONSET/OFFSET and RESPOND genotype studies Clin Cardiovasc Genet 3 2010 556 566
22. S.K. James, M.T. Roe, and C.P. Cannon PLATO study group. Ticagrelor vs clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial BMJ 342 2011 d3527
23. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor vs clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
24. M.A. Crouch, V.J. Colucci, P.A. Howard, and S.A. Spinler P2Y12 receptor inhibitors: integrating Ticagrelor into the management of acute coronary syndrome Ann Pharmacother 45 2011 1151 1156
25. D.L. Bhatt, A.M. Lincoff, and C.M. Gibson Intravenous platelet blockade with cangrelor during PCI N Engl J Med 361 2009 2330 2341
26. S. Leonardi, S.V. Rao, and R.A. Harrington Rationale and design of the randomized, double blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y8!")-receptor inhibitor, vs clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI) Am Heart J 160 2010 65 72
27. R.C. Becker, D.J. Moliterno, and L.K. Jennings Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomized, double-blind, placebo-controlled phase II study TRA-PCI Investigators. Lancet 373 2009 872 873
28. L.A. Garcia Rodriguez, K.J. Lin, S. Hernandez-Diaz, and S. Johansson Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications Circulation 123 2011 1108 1115
29. G. Rose Strategy of prevention: lessons from cardiovascular disease Br Med J (Clin Res Ed) 282 1981 1947 1951
30. A. Tosetto The unresolved challenge of subjects at intermediate cardiovascular risk Intern Emerg Med 6 2011 297 298
31. C. Baigent, L. Blackwell, and R. Collins Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Antithrombotic Trialists' (ATT) Controlled Trial JAMA 303 2010 841 848
32. M. Pignone, M.J. Alberts, and J.A. Colwell Aspirin for primary prevention of cardiovascular events in people with diabetes J Am Coll Cardiol 55 2010 2878 2886
33. S.H. Simpson, J.M. Gamble, L. Mereu, and T. Chambers Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis J Gen Intern Med 26 2011 1336 1344
34. A.A. Bartolucci, M. Tendera, and G. Howard Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin Am J Cardiol 107 2011 1796 1801
35. N. Raju, M. Sobierai-Teague, J. Hirsh, M. O'Donnell, and J. Eikelboom Effect of aspirin on mortality in the primary prevention of cardiovascular disease Am J Med 124 2011 621 629